acetate salt raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-12-19 and is reviewed periodically as new material appears.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
=== Systematic reviews identifying safety signals === A 2013 comprehensive systematic review by Dr. Salvatore Gentile concluded that second‑generation long‑acting injectable antipsychotics (SGA‑LAIs) "seem to also show unforeseen and worrisome safety signals," and noted that "worsening of psychotic symptoms and depression could also be associated with both risperidone‑LAI and paliperidone palmitate." The leading cause of death among patients enrolled in risperidone‑LAI studies was suicide. A 2017 systematic update by the same author concluded that SGA‑LAIs "do not offer advantages in safety compared with first‑generation antipsychotic LAIs or oral antipsychotics," and highlighted weight gain, hyperprolactinemia, and the finding that the three‑monthly paliperidone palmitate formulation still lacked exhaustive safety data.
== Uses == Synthetic platelets have diverse therapeutic applications, including treating hemostasis in trauma care, clotting disorders, and immune responses in conditions such as thrombosis, inflammation, and cancer. Originally researched to replicate the biochemistry and cell and molecular biology of natural platelets, platelet-mimicking particles are now in preclinical development for multiple therapeutic applications with specialized drug delivery mechanisms. The need for these particles is informed by increasing rates of reported thrombocytopenia cases and clinical bleeding syndrome diagnoses such as von Willebrand disease or Glanzmann thrombasthenia. Early treatment solutions of the mid-late twentieth century were not based upon current findings in nanoparticle drug delivery technologies, thus lacking the ability to overcome primary limitations of natural platelets. With a diverse assortment of platelet-mimicking particle formulations under testing, their use can be widespread to multiple clinical diagnoses and areas—antimicrobial platelets, cancer, hemorrhage and trauma, bleeding disorders, and cholesterol clearance.
=== Epstein–Barr virus === Spironolactone has been found to block Epstein–Barr virus (EBV) production and that of other human herpesviruses by inhibiting the function of an EBV protein SM, which is essential for infectious virus production. This effect of spironolactone was determined to be independent of its antimineralocorticoid actions.
Russian forces targeted Kyiv and the Odesa region according to Ukrainian authorities. Explosions were heard over Kyiv with one garage complex being set on fire by falling debris in the Darnytskyi District and another fire breaking out in Desnianskyi District. In Odesa, one person was reported killed and two wounded when an "industrial object" was struck. The missiles used were Kh-101s and Kh-55s, reportedly fired from strategic bombers. Airstrikes were also reported in Vinnytsia and Khmelnytskyi Oblasts. The Ukrainian Air Force, in a statement, claimed 29 of the 30 missiles were intercepted. This was the ninth air raid aimed at Kyiv this month. The Russian Defence Ministry claimed to have destroyed all its designated targets in the airstrikes, including weapons and ammunitions stocks. A train between Simferopol and Sevastopol, on Crimea, was derailed by an explosion causing the suspension of rail traffic between the two cities. Wagner Group head Yevgeny Prigozhin again complained, in a video message, of setbacks by the Russian military in Bakhmut, claiming that they had withdrawn up to 570 meters (1,870 feet) to the north of the city, exposing Wagner's flanks. He claimed that Wagner mercenaries had advanced up to 400 meters inside the city, while the Ukrainian Defence Ministry said its forces had advanced 500 meters in the north of the city and up to one kilometer in the south side while retaining the southwestern part of Bakhmut. Hussein Dzhambetov, a commanding officer from the pro-Ukrainian Chechen Separate Special Purpose Battalion defected to Russia.
Sources: en.wikipedia.org
Singapore and Sri Lanka. ISCEA's Certified Lean Master (CLM) programme is delivered in Hong Kong and Malaysia through SGS, the global inspection, verification, testing and certification entity. In 2019 Tim Charlton was appointed to the position of President of ISCEA-Pacific (Australia and New Zealand) and also appointed to the ISCEA- APAC Board that included Mr. Ejazur Rahman (Bangladesh) CEO, ISCEA-Asia, Mr. Nikhil Oswal (India), CEO, ISCEA-India, Dr. Premkumar Rajagopal (Malaysia), President, MUST (Malaysia University of Science and Technology), Mr. Sandeep Chatterjee (India), Senior Manager, Deloitte India, Dr. Nyoman Pujawan, Ph.D., (Indonesia), Professor, Institut Teknologi Sepuluh Nopember, and Dr. Harish Pant (India), Chief Business Transformation Officer, NTF (India) Pvt. Ltd. In 2024, ISCEA started a partnership with Singapore-based SCALA - Supply Chain and Logistics Academy. SCALA (Singapore) and PPLC Superport & Industrial Co., LTD. (Cambodia) signed a historic Memorandum of Understanding (MoU) to train up to 300 Cambodian trainees in Singapore. The training included hands-on experiential learning and certification as Certified Supply Chain Analysts from ISCEA. The MoU signing was further marked at the Cambodia-Singapore Business Forum in the presence of Samdech Moha Borvor Thipadei Hun Manet, Prime Minister of the Kingdom of Cambodia.
==== Alcohol-ether treatment ==== This treatment follows the similar treatment of the PEG solution but instead of replacing the cells with another solution, the cells are replaced with alcohol and when the alcohol evaporates the cell and overall object is dehydrated. As a volatile solvent treatment option, the impact on the health and safety on the workplace must be considered.
Techniques such as using dendritic cells or regulatory T cells engineered to promote tolerance to beta cells are being studied in clinical trials, though these approaches remain experimental. There is evidence suggesting that certain viral infections may trigger type 1 diabetes. Systematic review and meta-analyses of 60 studies indicated that exposure to enteroviruses increases the risk. Enterovirus B, Enterovirus C, coxsackievirus B1, and coxsackievirus B4 were associated with elevated risk. Infections during pregnancy have also been associated with an increased risk of type 1 diabetes in the offspring, with enteroviruses, rubella virus, and cytomegalovirus showing elevated risk. Vaccination against rotavirus in young children has been associated with a reduction in incidence rates of type 1 diabetes. Countries that implemented a nationwide rotavirus vaccination program have shown a decline in the incidence of type 1 diabetes in young children (<5 years of age) The results were more marked with the pentavalent rotavirus vaccine than the monovalent vaccine. Combination immunotherapies are being explored to achieve more durable immune protection by using multiple agents together. For example, anti-CD3 antibodies may be combined with other immunomodulatory agents such as IL-1 blockers or checkpoint inhibitors. Finally, researchers are studying how environmental factors such as infections, diet, and stress may affect immune regulation through epigenetic modifications.
Sources: en.wikipedia.org
The education system of Malaysia features a non-compulsory kindergarten education followed by six years of compulsory primary education and five years of optional secondary education. Schools in the primary education system are divided into two categories: national primary schools, which teach in Malay (i.e.:Sekolah Kebangsaan Sungai Binjai, SK Bukit Tiu), and vernacular schools, which teach in Chinese or Tamil (i.e.:SJK(C) Pin Hwa 2, SJK(T) Bandar Mentakab). Secondary education (i.e.:SMK Sura, Kajang High School) is conducted for five years. In the final year of secondary education, students sit for the Malaysian Certificate of Education examination. Since the introduction of the matriculation programme in 1999, students who completed the 12-month programme in matriculation colleges can enrol in local universities. However, in the matriculation system, only 10% of places are open to non-bumiputera students.
Hydrazones are a class of organic compounds with the structure R1R2C=N−NH2. They are related to ketones and aldehydes by the replacement of the oxygen =O with the =N−NH2 functional group. They are formed usually by the action of hydrazine on ketones or aldehydes.
==== Myosin storage myopathy ==== In myosin storage myopathies, myosin accumulates beneath sarcolemma and between myofibrils, forming protein aggregates. A myopathy associated with the gene MYH7 is autosomal dominant myosin storage congenital myopathy-7A (CMYP7A).
1993/3156) European Communities (Definition of Treaties) (European Investment Fund) Order 1993 (S.I. 1993/3157) Drug Trafficking Offences Act 1986 (Designated Countries and Territories) (Amendment) (No. 2) Order 1993 (S.I. 1993/3158) Environment and Safety Information (Northern Ireland) Order 1993 (S.I. 1993/3159) Roads (Northern Ireland) Order 1993 (S.I. 1993/3160) Merchant Shipping (Fire Protection) (Non-United Kingdom) (Non-SOLAS Ships) (Amendment) Rules 1993 (S.I. 1993/3161) Merchant Shipping (Fire Appliances) (Amendment) Regulations 1993 (S.I. 1993/3162) Merchant Shipping (Fire Protection) (Amendment) Regulations 1993 (S.I. 1993/3163) Merchant Shipping (Fire Protection) (Ships Built Before 25 May 1980) (Amendment) Regulations 1993 (S.I. 1993/3164) Water and Sewerage Services (Amendment) (Northern Ireland) Order 1993 (S.I. 1993/3165) Ministerial and other Salaries Order 1993 (S.I. 1993/3166) Redundancy Payments (National Health Service) (Modification) Order 1993 (S.I. 1993/3167) Finance Act 1985 (Interest on Tax) (Prescribed Rate) (No. 2) Order 1993 (S.I. 1993/3168) Local Government Act 1992 (Commencement No. 3) Order 1993 (S.I. 1993/3169) Town and Country Planning (Fees for Applications and Deemed Applications) (Amendment) Regulations 1993 (S.I. 1993/3170) Taxes (Interest Rate) (Amendment No. 4) Regulations 1993 (S.I. 1993/3171) National Health Service (General Dental Services) Amendment (No. 2) Regulations 1993 (S.I. 1993/3172) Commercial Agents (Council Directive) (Amendment) Regulations 1993 (S.I.
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.